Proteins that bind folate receptor alpha including fully-human antibodies
This disclosure describes proteins that specifically bind human folate receptor alpha (FRalpha) with high affinity. These proteins include a recombinant human anti-FRalpha IgG1 that is suitable for use as a therapeutic antibody to treat cancers that express FRalpha. Other FRalpha-binding proteins are also described including antibody fragments, antibody conjugates, and fusion proteins.
1. A recombinant anti-folate receptor alpha antibody, comprising:
a heavy chain that has at least 90 percent sequence homology with SEQ ID NO: 11, wherein the heavy chain comprises SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; and
a light chain that has at least 90 percent sequence homology with SEQ ID NO: 12, wherein the light chain comprises SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
2. A recombinant anti-folate receptor alpha antibody or antigen-binding fragment thereof, comprising:
a first variable domain that comprises a VH CDR1 region including an amino acid sequence comprising SEQ ID NO: 5, a VH CDR2 region including an amino acid sequence comprising SEQ ID NO: 6, and a VH CDR3 region including an amino acid sequence comprising SEQ ID NO: 7; and
a second variable domain that comprises a VL CDR1 region including an amino acid sequence comprising SEQ ID NO: 8, a VL CDR2 region including an amino acid sequence comprising SEQ ID NO: 9, and a VL CDR3 region including an amino acid sequence comprising SEQ ID NO: 10; and
wherein the antibody or antigen-binding fragment thereof binds human folate receptor alpha.
3. The recombinant anti-folate receptor alpha antibody of claim 2 , further comprising:
a third variable domain that comprises a VH CDR1 region including an amino acid sequence comprising SEQ ID NO: 5, a VH CDR2 region including an amino acid sequence comprising SEQ ID NO: 6, and a VH CDR3 region including an amino acid sequence comprising SEQ ID NO: 7; and
a fourth variable domain that comprises a VL CDR1 region including an amino acid sequence comprising SEQ ID NO: 8, a VL CDR2 region including an amino acid sequence comprising SEQ ID NO: 9, and a VL CDR3 region including an amino acid sequence comprising SEQ ID NO: 10.
4. The recombinant anti-folate receptor alpha antibody or antigen-binding fragment thereof of claim 2 , further comprising a dissociation constant (KD) with human folate receptor alpha of no greater than 25 nanomolar.
5. The recombinant anti-folate receptor alpha antibody or antigen-binding fragment thereof of claim 4 , wherein the KD is determined by enzyme-linked immunosorbent assay.
6. The recombinant anti-folate receptor alpha antibody of claim 2 , further comprising:
a human IgG1 heavy chain constant region; and
a human kappa light chain constant region.
7. The recombinant anti-folate receptor alpha antibody of claim 2 , further comprising:
a human IgG1, IgG2, IgG3, or IgG4 heavy chain constant region; and
a human kappa light chain constant region.
8. The recombinant anti-folate receptor alpha antibody of claim 7 , wherein:
the antibody has a heavy chain that has at least 90 percent sequence identity with SEQ ID NO: 11; and
the antibody has a light chain that has at least 90 percent sequence identity with SEQ ID NO: 12.
9. The recombinant anti-folate receptor alpha antibody of claim 7 , comprising two heavy chains and two light chains, wherein:
each of the two heavy chains has at least 90 percent sequence identity with SEQ ID NO: 11; and
each of the two light chains has at least 90 percent sequence identity with SEQ ID NO: 12.
10. The recombinant anti-folate receptor alpha antibody of claim 2 , comprising at least four variable domains, wherein:
the first and second variable domains are paired in the antibody such that the first and second variable domains bind an epitope of human folate receptor alpha; and
the antibody comprises a third variable domain and a fourth variable domain that are paired in the antibody such that the third and fourth variable domains bind a different epitope.
11. An antibody conjugate comprising the recombinant anti-folate receptor alpha antibody of claim 2 conjugated to a radioactive isotope.
12. The antibody conjugate of claim 11 , wherein the radioactive isotope is actinium-225, astatine-211, bismuth-212, bismuth-213, copper-67, gallium-68, holmium-166, iodine-124, iodine-131, lutetium-177, samarium-153, technetium-99, terbium-149, or yttrium-90.
13. An antibody conjugate comprising the recombinant anti-folate receptor alpha antibody of claim 2 , conjugated to a pharmaceutical agent.
14. The antibody conjugate of claim 13 , wherein the antibody is conjugated to a moiety selected from a amanitin, 3-aminophenyl hemiasterlin, calicheamicin, camptothecin, deruxtecan, doxorubicin, emtansine, eribulin, exatecan, irinotecan, maleimidocaproyl monomethyl auristatin F, maytansine, mertansine (N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine; DM1), monomethyl auristatin F, paclitaxel, PE38, pyrrolobenzodiazepine, ravtansine (N2′-deacetyl-N2′-(4-mercapto-4-methyl-1-oxopentyl) maytansine; DM4), SN-38, and vedotin.
15. A pharmaceutical composition, comprising:
the recombinant anti-folate receptor alpha antibody of claim 2 ; and
a pharmaceutically acceptable carrier.
16. A kit, comprising:
a hermetically-sealed container that contains the pharmaceutical composition of claim 15 .
17. A medical device, comprising the pharmaceutical composition of claim 15 , wherein the medical device is a syringe, a venous cannula, or a drug-eluting implant.
18. A kit, comprising the recombinant anti-folate receptor alpha antibody of claim 2 and a reporter that comprises either (i) a conjugated dye or (ii) a conjugated fluorescent, phosphorescent, chemiluminescent, radioactive, or magnetic label, wherein the kit is configured to detect folate receptor alpha in a biological sample.
19. A recombinant anti-folate receptor alpha antibody or antigen-binding fragment thereof, comprising:
a first variable domain that comprises an amino acid sequence comprising SEQ ID NO: 3, wherein the first variable domain comprises SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7;
a second variable domain that comprises an amino acid sequence comprising SEQ ID NO: 4, wherein the second variable domain comprises SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10; and
wherein the antibody or antigen-binding fragment thereof binds human folate receptor alpha.
20. The recombinant anti-folate receptor alpha antibody of claim 19 , wherein:
the antibody further comprises a third variable domain that comprises an amino acid sequence comprising SEQ ID NO: 3; and
the antibody further comprises a fourth variable domain that comprises an amino acid sequence comprising SEQ ID NO: 4.